Tranexamic Acid to Improve Arthroscopic Visualization in Shoulder Surgery

• Status: Active, not recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if intravenous TXA is a safe alternative to epinephrine in improving arthroscopic shoulder visualization.

Primary Objectives

1. Determine that patients given intravenous tranexamic acid improves surgeon-rated visualization compared to placebo.

2. Determine that intravenous tranexamic acid is a safe alternative to epinephrine mixed irrigation fluid to improve arthroscopic shoulder visualization

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Panam Clinic
• Collaborator: University of Manitoba
• Treatments: Epinephrine; Epinephryl borate; Racepinephrine; Tranexamic Acid

Criteria

Inclusion Criteria:

• Able to read and understand patient consent form and give informed consent

• Rotator cuff pathology or impingement that have clinical indications for shoulder arthroscopy surgery (either rotator cuff repair or subacromial decompression

Exclusion Criteria:

• Have an active thromboembolic event

• Allergies or hypersensitivies to TXA or any of the ingredients

• Have a seizure disorder

• On hormonal contraceptives

• Pregnant

• History of venous thromboembolism in the previous 12 months, or requiring lifelong anticoagulation related to previous VTE. VTE is defined as a cerebrovascular event (stroke, transient ischemic attack, deep vein thrombosis, and pulmonary embolism or with a history of hypercoagulable disorders (i.e. Factor V Lieden, antiphospholipid antibody)

• Acquired disturbances of colour vision

• Hematuria with renal cause